Table 3

Results of a zero-inflated negative binomial regression analysis of the association between cumulative days supplied and average daily MED in the first 8 weeks after injury and days on benefits and benefit status after the 8-week exposure window up to 1 year after injury

PredictorDays on benefits after exposure windowOn benefits after exposure window
IRR (95% CI)OR (95% CI)
UnadjustedAdjustedUnadjustedAdjusted
Cumulative days’ supply in first 8 weeks
 Opioids (n=26 673)
 For every 7-day increase1.10 (1.09 to 1.11)1.10 (1.09 to 1.11)*1.32 (1.30 to 1.35)1.35 (1.33 to 1.39)*
 NSAIDs (n=39 571)
 For every 7-day increase1.07 (1.06 to 1.08)1.04 (1.03 to 1.05)†1.37 (1.35 to 1.39)1.25 (1.23 to 1.28)†
 SMRs (n=23 837)
 For every 7-day increase1.07 (1.05 to 1.08)1.03 (1.01 to 1.04)‡1.41 (1.37 to 1.43)1.23 (1.20 to 1.27)‡
Average daily MED in first 8 weeks (n=29 818)
 For every 30 mg/day increase1.06 (1.04 to 1.09)1.04 (1.02 to 1.07)§1.02 (0.99 to 1.05)1.02 (0.99 to 1.04)§
  • *Adjusted for sex, age, year of injury, income, cumulative days of opioids in previous year.

  • †Adjusted for sex, age, year of injury, income, cumulative days of opioids within 8 weeks, diagnosis code, cumulative days of SMRs within 8 weeks, spine X-ray within first 8 weeks.

  • ‡Adjusted for sex, age, year of injury, income, cumulative days of opioids within 8 weeks, cumulative days of NSAIDs within 8 weeks, spine X-ray within first 8 weeks.

  • §Adjusted for sex, age, year of injury, income, diagnosis code, spine X-ray within first 8 weeks, pain specialist visit within first 8 weeks, health authority, NSAID dispense within first 8 weeks, cumulative days of opioids in previous year, anticonvulsant dispense within first 8 weeks.

  • IRR, incidence rate ratio; MED, morphine-equivalent dose; NSAID, non-steroidal anti-inflammatory drug; SMR, skeletal muscle relaxant.